简化抗逆转录病毒疗法：对我们的患者以及我们医疗保健系统的可持续性而言是一个不错的选择。
Simplification of antiretroviral therapy: a good choice for our patients and the sustainability of our health care system.
作者信息
González Rivas L, Sánchez Gómez E, Sánchez del Moral R, Grutzmancher Saiz S, Pujol de la Llave E, Bocanegra Martín C
机构信息
Servicio de Farmacia, Hospital General de Especialidades Juan Ramón Jiménez, Huelva, España.
出版信息
Farm Hosp. 2011 Nov-Dec;35(6):317-21. doi: 10.1016/j.farma.2011.01.003. Epub 2011 Oct 21.
OBJECTIVE
To describe the efficacy, safety, compliance and cost savings of lopinavir/ritonavir monotherapy.
METHOD
Observational, descriptive and retrospective study evaluating monotherapy. Adherence was calculated using an objective method. We estimated the direct costs of dispensing non-triple therapy.
RESULTS
We identified 17 patients. Interval adherence was > 95% in 9 patients, 90-95% in 2 patients, 90-85% in 2 patients, and less than 85% in 4 patients. Viral load was undetectable during weeks 12, 24, 36 and 48, except in 2 patients. The CD4 count in most analytical tests remained at > 350 cells/ml, only 1 patient had a lower figure. The average savings was 4819 Euros/patient/year (range 1116 to 8700).
CONCLUSIONS
In selected patients, monotherapy can be a cost-effective treatment option.
目的
描述洛匹那韦/利托那韦单药治疗的疗效、安全性、依从性及成本节约情况。
方法
对单药治疗进行观察性、描述性和回顾性研究。采用客观方法计算依从性。我们估算了非三联疗法的配药直接成本。
结果
我们纳入了17例患者。9例患者的间期依从性>95%，2例患者为90 - 95%，2例患者为90 - 85%，4例患者低于85%。除2例患者外，在第12、24、36和48周时病毒载量均检测不到。大多数分析检测中的CD4细胞计数保持在>350个细胞/毫升，只有1例患者数值较低。平均节约成本为4819欧元/患者/年（范围为1116至8700欧元）。
结论
在选定的患者中，单药治疗可能是一种具有成本效益的治疗选择。
Zotero 插件